NCT00303732View on ClinicalTrials.gov

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2012

Conditions

Kidney CancerUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

RAD001 (everolimus)

DRUG

PTK787 (vatalanib)

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Daniel George, MD

OTHER

NCT00303732 - Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter